Madrigal Pharmaceuticals, Inc.
corporate_fare Company Profile
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for MDGL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-06, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for MDGL spans 4, 10-Q, 8-K, DEF 14A.
Recent high-impact activity:
- Baker Bros. Buys $35M of Madrigal Stock Days After First Profitable Quarter
- One-Year Rezdiffra Data Shows Liver Stiffness Improvement in Up to 93% of Patients
- Madrigal 10-Q Details First Profitable Quarter, $961.8M Cash, EPS Restatement and New SOX Suit
- Madrigal Posts First Profitable Quarter as Rezdiffra Sales Hit $431.3M
- Madrigal Posts $1.83 Third-Quarter EPS
Financial Snapshot
Short Interest & Short Volume
7.64 days to coverFINRA reported short interest of 2,136,404 shares in MDGL as of the October 30, 2026 settlement, a 2.6% decrease from the prior period — about 7.6 days to cover at its recent average daily volume. On November 20, 2026, 39.4% of MDGL volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.